[Tailored therapy in gastrointestinal and hepatic cancer--toward ideal medicine through genomic science].
Imai
Kohzoh
K
First Department of Internal Medicine, Sapporo Medical University School of Medicine.
Yoshida
Yukinari
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000378:metabolism; D001549:Benzamides; D000068258:Bevacizumab; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004798:Enzymes / Q000235:genetics; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D018390:Gene Targeting; D015316:Genetic Therapy; D023281:Genomics; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D020411:Oligonucleotide Array Sequence Analysis; D010597:Pharmacogenetics; D010879:Piperazines / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D011743:Pyrimidines / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D004798:Enzymes; D010879:Piperazines; D011743:Pyrimidines; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000068877:Imatinib Mesylate